explore -WSS

explore

author：leisure time 2025-10-02 00:29:47 - browse：786

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Why palliative psychiatry is worth discussing

explore

WSS

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Medicare inequities exacerbate Puerto Rico’s health disparities

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Alabama frozen embryo ruling has major implications for IVF clinics

PBM reform efforts get punted in Congress

Medicare inequities exacerbate Puerto Rico’s health disparities

entertainment

explore

leisure time

How to save PrEP access — and even expand it

Air quality improving but still lags in Black, Hispanic communities

Alkermes shareholders re

Antivenom research: Lessons from HIV applied in search for universal antidote

Cancer drug shortages should be causing more outrage

In utero gene editing: an explainer

New air purifier tech could be key to improving indoor air quality

NIH study of ME/CFS points to clear biological hallmarks

United colonoscopy coverage change 'may cost lives,' doctors say

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

leisure time

A new nitrogen execution bill also undermines medical licensing

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Just how do doctors, lawmakers, and the public define abortion?

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

CDC marks new Covid

leisure time

explore

focus

focus